MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2015
At a glance
- Drugs MM 111 (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Merrimack Pharmaceuticals
- 03 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2012 Planned number of patients changed from 39 to 21 as reported by ClinicalTrials.gov.
- 06 Jun 2012 Planned End Date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.